A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
Key facts
- Who runs it
- Zhejiang Doer Biologics Co., Ltd.
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 378 people, planned
- Started
- Aug 2026
- Expected to end
- Oct 2030
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- DR10624 Subcutaneous Injection
- Icosapent Ethyl Oral Capsule
- Matching Placebo Subcutaneous Injection
- Record updated
- 6 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age ≥18 years, male or female; BMI 19.0-45.0 kg/m², body weight ≥50 kg at screening
- Fasting triglyceride (TG) range 5.65-22.60 mmol/L: single screening lab result meets range, plus average of two separate fasting TG tests (interval >1 week) within same range prior to randomization
- Stable lipid-lowering medications per local guidelines if on statin, cholesterol absorption inhibitor or PCSK9 inhibitor (minimum stable dose duration as required by drug class)
- Females of childbearing potential agree effective contraception from ICF signing to 2 months post last dose; male participants agree contraception and no sperm donation for 3 months post last dose
- Able to understand study procedures, maintain consistent lifestyle and follow all protocol-specified requirements, and provide written informed consent
Who cannot take part
- Prior GLP-1/GCGR/FGF21 agonists or other investigational drugs within 3 months
- Confirmed hereditary lipid disorders (Fredrickson Type 1/3, Apo C-II deficiency)
- Severe chronic liver, renal or advanced cardiac disease
- Uncontrolled diabetes or hypertension with severe complications
- Pancreatitis history or symptomatic gallbladder disease
- Recent major cardiovascular, bone or thyroid disorders
- Severe psychiatric illness or substance abuse history
- Abnormal screening lab parameters related to liver, pancreas, kidney or viral infection
- Pregnant, breastfeeding or hypersensitivity to study treatments
- Significant weight loss or planned weight reduction during study
- Investigator's judgment of unsuitability for participation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus lifestyle management. Eligible participants complete a screening run-in period, then randomize equally to three treatment groups: two active DR10624 subcutaneous injection groups and one placebo group. All subjects maintain fixed oral background lipid therapy throughout long-term double-blind treatment, followed by a short safety follow-up period. The primary objective is to evaluate the triglyceride-lowering effect of DR10624 versus placebo. Secondary assessments include other lipid indicators, liver fat content, overall safety, and anti-drug antibody status. Independent committees monitor interim data and adjudicate key clinical events to ensure participant safety.
The 3 groups in the trial
- Experimental Group 1: Weekly DR10624 InjectionTreatment being tested
Treatment: DR10624 Subcutaneous Injection and Icosapent Ethyl Oral Capsule
- Experimental Group 2: Weekly DR10624 InjectionTreatment being tested
Treatment: DR10624 Subcutaneous Injection and Icosapent Ethyl Oral Capsule
- Weekly Matching Placebo InjectionPlacebo, for comparison
Treatment: Icosapent Ethyl Oral Capsule and Matching Placebo Subcutaneous Injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of DR10624 Added to Standard Icosapent Ethyl Therapy in Adults With Severe Hypertriglyceridemia
- Record updated
- 6 July 2026